MX2020005238A - Compuestos novedosos como inhibidores mpges-1. - Google Patents

Compuestos novedosos como inhibidores mpges-1.

Info

Publication number
MX2020005238A
MX2020005238A MX2020005238A MX2020005238A MX2020005238A MX 2020005238 A MX2020005238 A MX 2020005238A MX 2020005238 A MX2020005238 A MX 2020005238A MX 2020005238 A MX2020005238 A MX 2020005238A MX 2020005238 A MX2020005238 A MX 2020005238A
Authority
MX
Mexico
Prior art keywords
mpges
compounds
expression
activity
diseases
Prior art date
Application number
MX2020005238A
Other languages
English (en)
Spanish (es)
Inventor
Julien David Beyrath
Johannes Albertus Maria Smeitink
Original Assignee
Khondrion Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khondrion Ip B V filed Critical Khondrion Ip B V
Publication of MX2020005238A publication Critical patent/MX2020005238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020005238A 2017-11-22 2018-11-22 Compuestos novedosos como inhibidores mpges-1. MX2020005238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203033 2017-11-22
PCT/EP2018/082146 WO2019101826A1 (en) 2017-11-22 2018-11-22 Compounds as mpges-1 inhibitors

Publications (1)

Publication Number Publication Date
MX2020005238A true MX2020005238A (es) 2020-08-24

Family

ID=60450482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005238A MX2020005238A (es) 2017-11-22 2018-11-22 Compuestos novedosos como inhibidores mpges-1.

Country Status (16)

Country Link
US (1) US11672787B2 (https=)
EP (1) EP3713564B1 (https=)
JP (2) JP7754623B2 (https=)
KR (2) KR20200090818A (https=)
CN (1) CN111417393A (https=)
AU (1) AU2018371153B2 (https=)
BR (1) BR112020010089A2 (https=)
CA (1) CA3079483A1 (https=)
ES (1) ES2963906T3 (https=)
IL (1) IL274821A (https=)
MX (1) MX2020005238A (https=)
MY (1) MY207603A (https=)
PL (1) PL3713564T3 (https=)
SG (1) SG11202003743SA (https=)
WO (1) WO2019101826A1 (https=)
ZA (1) ZA202002103B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102660473B1 (ko) * 2017-04-05 2024-04-24 콘드리온 아이피 비.브이. 미토콘드리아 질환의 신규 치료
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2025730B1 (en) * 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
WO2025242849A1 (en) * 2024-05-24 2025-11-27 Khondrion Ip B.V. Chromanyl derivatives for use in the treatment of bone disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02250831A (ja) * 1989-03-23 1990-10-08 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
AU2005316091B2 (en) 2004-12-17 2011-12-01 Merck Canada Inc. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors
DE102006053475A1 (de) 2006-11-14 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
DE102006058450A1 (de) 2006-12-12 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009130242A1 (en) 2008-04-23 2009-10-29 Novasaid Ab Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
DE102008027331A1 (de) 2008-06-07 2009-12-10 Friedrich-Alexander-Universität Erlangen-Nürnberg Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en) 2011-11-16 2013-05-23 Glenmark Pharmaceuticals S.A. Phtalazinone derivatives as mpegs -1 inhibitors
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013153535A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
HUE033757T2 (en) 2012-07-12 2017-12-28 Khondrion Ip B V Chromanyl derivatives for treating mitochondrial disease
HRP20170532T4 (hr) * 2012-07-12 2019-12-27 Khondrion Ip B.V. Derivati kromanila za liječenje mitohondrijske bolesti
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
PT3133068T (pt) 2014-04-14 2021-01-06 Shanghai hengrui pharmaceutical co ltd Derivados de amida e sais farmacêuticos destes, método de preparação destes e aplicação medicinal destes
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
ES2927699T3 (es) * 2015-05-22 2022-11-10 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de nefropatía diabética o enfermedad renal diabética
ES3033538T3 (en) 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
KR102660473B1 (ko) * 2017-04-05 2024-04-24 콘드리온 아이피 비.브이. 미토콘드리아 질환의 신규 치료
EP3713563B1 (en) * 2017-11-22 2025-02-19 Khondrion Ip B.V. Amide derivatives of chromanyl or chromanyl quinones for use in treating depression and migraine

Also Published As

Publication number Publication date
EP3713564C0 (en) 2023-11-15
CN111417393A (zh) 2020-07-14
JP2021504307A (ja) 2021-02-15
MY207603A (en) 2025-03-06
KR20200090818A (ko) 2020-07-29
IL274821A (en) 2020-07-30
US20200345706A1 (en) 2020-11-05
KR20250109241A (ko) 2025-07-16
ZA202002103B (en) 2023-12-20
CA3079483A1 (en) 2019-05-31
BR112020010089A2 (pt) 2020-11-03
JP7754623B2 (ja) 2025-10-15
EP3713564B1 (en) 2023-11-15
US11672787B2 (en) 2023-06-13
AU2018371153B2 (en) 2023-07-13
WO2019101826A1 (en) 2019-05-31
ES2963906T3 (es) 2024-04-03
PL3713564T3 (pl) 2024-04-08
RU2020120235A (ru) 2021-12-22
AU2018371153A1 (en) 2020-06-04
EP3713564A1 (en) 2020-09-30
SG11202003743SA (en) 2020-06-29
JP2024009799A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
SA518391624B1 (ar) Ror- منظمات جاما
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
MX2018002631A (es) Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MX2017007426A (es) Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX2020005238A (es) Compuestos novedosos como inhibidores mpges-1.
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CO2017004465A2 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
PH12017500913A1 (en) Substituted bridged urea analogs as sirtuin modulators
CL2022000758A1 (es) Tienopirimidonas como inhibidores de trpa1
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.